<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03467412</url>
  </required_header>
  <id_info>
    <org_study_id>FCS-002</org_study_id>
    <nct_id>NCT03467412</nct_id>
  </id_info>
  <brief_title>To Investigate Efficacy of FOL-005 on Hair Growth on Scalp Skin</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled Phase 2 Trial of FOL-005 to Investigate Efficacy on Hair Growth on Scalp Skin in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Follicum AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bioskin GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Follicum AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial is a multicentre, randomised, double-blind, placebo controlled phase 2 trial.

      60 healthy bald male subjects diagnosed with alopecia, who are between 18 and 55 years old
      and provide written informed consent will be eligible for inclusion.

      The trial period will consist of a screening period of up to 3 weeks followed by 12 weeks of
      dosing, three times per week. Each subject will receive two doses of the five trial treatment
      doses (placebo, 0.00625, 0.025, 0.050, and 0.100 μg respectively). The doses will be given as
      intradermal injections. On each volunteer, two treatment areas will be placed on the head and
      the two selected doses will be allocated to the respective treatment areas according to the
      randomisation scheme. The treatment areas will be selected on the border between the bald
      surface and the surface with hair.

      The effect on hair growth will be measured at week 8 and 12
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 5, 2018</start_date>
  <completion_date type="Anticipated">August 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the efficacy of FOL-005 on scalp hair density</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline of total hair density (No. of hairs per cm2) on the scalp</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Androgenic Alopecia</condition>
  <arm_group>
    <arm_group_label>0.00625 μg FOL-005</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.025 μg FOL-005</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.050 μg FOL-005</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.100 μg FOL-005</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOL-005</intervention_name>
    <description>intradermal injection</description>
    <arm_group_label>0.00625 μg FOL-005</arm_group_label>
    <arm_group_label>0.025 μg FOL-005</arm_group_label>
    <arm_group_label>0.050 μg FOL-005</arm_group_label>
    <arm_group_label>0.100 μg FOL-005</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>intradermal injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male, aged 18-55 years

          -  Androgenetic alopecia (AGA)) - Norwood/Hamilton grade 3V to 4/4a

          -  Caucasian, skin type I - IV according to Fitzpatrick's classification

        Exclusion Criteria:

          -  Any dermatological disorders of the scalp which might interfere with the application
             of Investigational Medical Product or examination method, such as fungal or bacterial
             infections, seborrheic dermatitis, psoriasis, eczema, folliculitis or scalp atrophy

          -  Any skin pathology (e.g. scar, nevus) or general condition (e.g. uncontrolled thyroid
             diseases) that in the investigator's opinion can interfere with the evaluation of the
             treatment areas or requires topical or systemic therapy

          -  History of active hair loss due to alopecia areata, scarring alopecia, diffuse telogen
             effluvium or conditions other than androgenetic alopecia

          -  Immunological disorders such as alopecia areata, and systemic lupus erythematosus and
             other systemic known autoimmune disorders

          -  Diabetes mellitus

          -  Coagulation deficiencies

          -  Topical treatments for hair growth (minoxidil, anti-androgens or other agents known to
             affect hair growth) in the last 6 months

          -  Topical treatments of the scalp including corticosteroids, tacrolimus, retinoids in
             the last 2 months or other treatments that may affect hair growth

          -  Platelet rich plasma (PRP) treatment on scalp during the last 12 months

          -  Systemic therapy using retinoids, cyclosporine within the last 3 months

          -  Systemic treatment with beta blockers or corticosteroids, scalp procedures e.g.
             surgery, laser, light, micro-needling within the last 6 months

          -  Finasteride (e.g. Propecia®) or Dutasteride intake in the last 12 months, or any
             systemic hair therapy medication in the last 12 months

          -  History of any acute (e.g. acute infections) or chronic illness (e.g. psoriasis,
             atopic dermatitis, porphyria) or known skin cancer that in the opinion of the
             investigators might confound the results of the trial

          -  History or clinical signs of keloids or hypertrophic scars

          -  Positive HIV-Antibody, HBs-Antigen or HCV-Antibody-Test at screening

          -  Current or within 2 weeks prior to first dosing use of vasodilating drugs (e.g.
             Pentoxifylline, nitroglycerine) or anticoagulating drugs (e.g. heparins, cumarins, new
             oral anticoagulants, regular intake of acetylsalicylic acid)

          -  Current or within 3 months prior to first dosing use of anti-inflammatory medication
             (ibuprofen, paracetamol is permitted), corticosteroids (nose drops, eye drops and/or
             inhalers are permitted) or immunosuppressive drugs taken for more than 2 consecutive
             weeks

          -  Hair transplantation at any time
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jan Alenfall, PhD</last_name>
    <phone>+46 (0)46 19 21 97</phone>
    <email>jan.alenfall@follicum.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Johan Quensel, PhD</last_name>
    <phone>+46 760466744</phone>
    <email>johan.quensel@follicum.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Klinik für Dermatologie, Venerologie und Allergologie, Charité-Universitätsmedizin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrike Blume-Peytavi, Professor</last_name>
      <phone>+49 (0)30 450 518 122</phone>
      <email>crc-office@charite.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bioskin GmbH</name>
      <address>
        <city>Hamburg</city>
        <zip>20095</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heinrich Siemetzki, MD</last_name>
      <phone>+494060689730</phone>
      <email>heinrich.siemetzki@bioskinCRO.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2018</study_first_submitted>
  <study_first_submitted_qc>March 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2018</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

